Catalent (CTLT) reported $1.03 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 10.2%. EPS of -$0.24 for the same period compares to $0.67 a year ago.The reported revenue represents a surprise of +1.79% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being -$0.03, the EPS surprise was -700.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023. “I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments. We also continued to invest in our operational improveme ...

Key PointsFinancials, healthcare, utilities and energy often, but not always, perform well when interest rates remain high.Demand for utilities and healthcare remains strong even in a high-rate environment, although the utilities sector has challenges related to capital investment and cost of borrowing.Energy is facing obstacles relating to geopolitical concerns and excess capacity. 5 stocks we like better than AlphabetLarge bank stocks such as Berkshire Hathaway Inc. NYSE: BRK.B, JPMorgan Chase & Co. NYSE: ...

Catalent’s (CTLT) shares rose 7.2% so far this week. The company’s share price surged following the announcement of its acquisition by Novo Holdings, the parent company of Novo Nordisk (NVO) .Catalent entered into a merger agreement with Novo Nordisk’s parent company on Feb 5. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The deal values Catalent at $16.5 billion on an enterprise value basis.The offered price for each share of CTLT repr ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: ZeroFox has agreed to be acquired by Havel ...

Catalent (CTLT) shares rallied 9.7% in the last trading session to close at $59.82. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.2% gain over the past four weeks.The sharp upsurge in Catalent's shares can be attributed to the announcement of a deal where the company will be acquired by Novo Holdings for $63.50 per share in cash. The deal puts an enterprise value of $16.5 billion on Catalent.This maker o ...

Shares of Catalent (CTLT 9.74%) rose by 9.7% on Monday after the pharmaceutical contract manufacturing and drug delivery technology specialist agreed to be acquired by Novo Holdings, the parent company of Novo Nordisk (NVO 4.01%).Novo Nordisk is bringing Catalent under its wingIn a press release Monday, Catalent announced it had agreed to be acquired by Novo Holdings for $63.50 per share in cash -- a 16.5% premium from Friday's closing price and a nearly 48% premium to its 60-day volume-weighted average pri ...

The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5 billion. The merger will help Novo meet strong demand for weight-loss drug Wegovy, increasing its filling capacity starting in 2026. On the charts, CTLT has been chopping higher since mid-November. Today's jump still isn't enough to close its April bear gap, though, which occurred after a Danaher (DHR) takeover ...

KEY TAKEAWAYSShares of Catalent soar on news Novo Holdings, the majority owner of Novo Nordisk, is acquiring the syringe maker for $16.5 billion in cash.The deal represents a 16.5% premium over Catalent's pre-announcement stock price Friday.The acquisition expands Novo Nordisk's production capacity and supply flexibility, particularly for its Wegovy weight loss drug.Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo No ...